Topical application of aprotinin in cardiac surgery

Isgro, Frank; Stanisch, Oliver; Kiessling, Arndt-H; Gürler, Semih; Hellstern, Peter; Saggau, Werner
September 2002
Perfusion;Sep2002, Vol. 17 Issue 5, p347
Academic Journal
The aim of our study was to compare a systemic and a local aprotinin application in patients during coronary artery bypass graft (CABG) surgery. The advantage of a topical aprotinin application is seen in the fact that this may not lead to systemic side effects. A prospective, randomized study comprising 97 patients was conducted. A dose of 5 × 10[sup 6] KIU aprotinin was given systemically to 49 patients and four doses of 1.25 × 10[sup 6] KIU aprotinin were applied topically to 48 patients by spraying the substance on the target area (A. mammaria interna region and pericardium). We determined markers for the inflammatory response, coagulation system, standard haematological markers and postoperative complications. Exclusion criteria were defined as surgical bleeding, redo operations, neurological, haematological, liver and kidney disorders. Sex, age, perfusion times, mortality, renal failure and strokes were identical in both groups. Biochemical markers and clinical outcome demonstrated no significant differences between the systemic and local applications. Interleukin 6 and elastase were tendentially higher (p = 0.1) in the local group, but with a high standard deviation in each patient. Our results suggest that there is no difference between the perioperative application of 5 × 10[sup 6] KIU systemically given aprotinin and 1.25 × 10[sup 6] KIU locally applied aprotinin.


Related Articles

  • Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation. Levy, Jerrold H. // American Journal of Health-System Pharmacy;9/15/2005 Supplement 4, Vol. 62, pS15 

    Purpose. The pharmacologic management of hemostasis in patients undergoing surgery with cardiopulmonary bypass is discussed. Summary. Nearly 45 studies involving 7,000 patients have reported efficacy of aprotinin in blood conservation. Both in primary coronary artery bypass graft (CABG)...

  • Review and application of serine protease inhibition in coronary artery bypass graft surgery. Engles, Laura // American Journal of Health-System Pharmacy;9/15/2005 Supplement 4, Vol. 62, pS9 

    Purpose. Current pharmacologic agents, aprotinin, epsilon aminocaproic acid, and tranexamic acid, used to decrease blood loss and transfusion requirements during coronary artery bypass graft (CABG) surgery are discussed. Aprotinin is the only agent that also modulates the systemic inflammatory...

  • Aprotinin associated with increased mortality after CABG.  // Reactions Weekly;2/17/2007, Issue 1139, p4 

    The article discusses research on the link of aprotinin use in patients undergoing coronary artery bypass graft surgery with an increased risk of long-term mortality. It references a study by D. T. Mangano et al in the February 7, 2007 issue of the "Journal of the American Medical Association."...

  • Comparison of two doses of aprotinin in patients receiving aspirin before coronary bypass surgery. Moran, S.V.; Lema, G.; Medel, J.; Irarrazaval, M.J.; Zalaquett, R.; Garayar, R. // Perfusion;Mar2000, Vol. 15 Issue 2, p105 

    This study was designed to evaluate efficacy and tolerability of two different doses of aprotinin in patients receiving aspirin before undergoing coronary artery bypass grafting. Forty-two patients were randomized to receive either placebo (group I), or aprotinin in doses of 4 000 000 KIU (group...

  • CABG Drug May Increase Likelihood of Death.  // RN;May2007, Vol. 70 Issue 5, p24 

    The article discusses research being done on mortality associated with aprotinin during five years following coronary artery bypass graft (CABG) surgery. It references a study by D. T. Mangano et al published in the 2007 issue of "JAMA." The study shows that patients treated with aprotinin...

  • Aprotinin.  // Reactions Weekly;7/26/2008, Issue 1212, p8 

    This article presents a case study involving a 67-year-old man, who had a history of repeated exposure to aprotinin-containing fibrin sealant, developed an anaphylactic reaction during prophylactic treatment with systemic aprotinin to reduce perioperative blood loss, during coronary bypass (CBP)...

  • The aprotinin saga and the risks of conducting meta-analyses on small randomised controlled trials -- a critique of a Cochrane review. Rosén, Måns // BMC Health Services Research;2009, Vol. 9, Special section p1 

    Background: Aprotinin for reducing blood loss during coronary artery bypass surgery was withdrawn from the market after early termination of a large randomised controlled trial (RCT) showing excess mortality for patients receiving aprotinin compared to lysine analogues. Several meta-analyses of...

  • Systemic inflammatory response to coronary artery bypass graft surgery. Hess Jr., Philip J. // American Journal of Health-System Pharmacy;9/15/2005 Supplement 4, Vol. 62, pS6 

    Purpose. Several aspects of the systemic inflammatory response to coronary artery bypass graft surgery are described. Summary. The inflammatory response is a fundamental biological protective mechanism that gathers together the body’s cellular and chemical defense mechanisms at the local...

  • Improving clinical outcomes in coronary artery bypass graft surgery. Sedrakyan, Artyom // American Journal of Health-System Pharmacy;9/15/2005 Supplement 4, Vol. 62, pS19 

    Purpose. Medical decisions are often made based on personal experience or on limited clinical trial information. Results from systematic reviews of clinical trials, however, provide a more thorough understanding of available data and can foster evidence-based decision making. Data from a recent...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics